AUTHORS
Yiao Di, Min Lang2, Lei Zhang, PhD3, Yang Song4, Hongguo Zhao5, Xiaobo Wang6, Liye Xu7, Rong Liang, MD8, Hui Liu, MD9, Xin Wan10, Huilai Zhang, PhD11, Hui Zhou12, Zengjun Li, MD13, Lu Zhang14, Liping Su, MD15, Haiyan Yang, PhD16, Jian Li, MD17, Wei Zhang18, Dao-Bin Zhou19, Yan Zhang, MD20
AFFILIATIONS
1 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
3 Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Henan 450052 Zhengzhou, China; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, China
4 Department of Hematology, Central Hospital of Dalian University of Technology, Dalian, China
5 The Affiliated Hospital of Qingdao University, Qingdao, China
6 The Second Hospital of Dalian Medical University, Dalian, China
7 The Second Hospital of Dalian Medical University, Dalian, China
8 Xijing Hospital,First Affiliated Hospital of Air Force Medical University, Xi'an, China
9 Beijing Hospital, Beijing, China
10 The First Hospital of Jilin University, Changchun, China
11 Tianjin Medical University Cancer Hospital, Tianjin, China
12 Hunan Cancer Hospital, Changsha, China
13 Cancer Hospital of Shandong First Medical University, Jinan, China
14 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 Shanxi Provincial Cancer Hospital, Taiyuan, China
16 Zhejiang Cancer Hospital, Hangzhou, China
17 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
18 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
19 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
20 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
ABSTRACT
Objective: Intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive lymphoma for which large multicenter real-world datasets are limited. We aimed to characterize its clinical features and treatment patterns, compare treatment responses and survival outcomes among patients receiving R-CHOP alone versus the addition of methotrexate (MTX) or a Bruton tyrosine kinase inhibitor (BTKi; e.g., zanubrutinib), and explore the outcomes of autologous hematopoietic stem cell transplantation (auto-HSCT) as frontline consolidation or salvage therapy.
Methods: This multicenter cohort study included 198 patients with biopsy-confirmed IVLBCL diagnosed at 14 hospitals in China between March 2014 and December 2025. Baseline characteristics, sites of involvement, PET/CT findings, treatment and responses, and follow-up data were collected. Treatment responses were compared across regimens. Survival was estimated using the Kaplan-Meier method.
Results: The median age was 62 years (interquartile range, 55-69), and 101 patients (51.0%) were male. Overall, 96.5% had Ann Arbor stage III-IV disease, including 187 with stage IV disease. The median International Prognostic Index (IPI) score was 4, and 148 patients (76.3%) were in the high-risk group (IPI 4-5). Bone marrow, central nervous system (CNS), skin, and lung involvement occurred in 102 (51.5%), 65 (32.8%), 95 (48.0%), and 89 patients (44.9%), respectively; 68 (34.3%) had hemophagocytic lymphohistiocytosis(HLH). Among 167 patients evaluated by PET/CT, 145 (86.8%) had abnormally increased metabolic activity.
Regarding treatment patterns and outcomes, 153 patients were included in comparative analyses: 6 received R-CHOP alone, 20 R-CHOP plus MTX, 72 R-CHOP plus a BTKi, and 25 R-CHOP plus both a BTKi and MTX. Seven received a polatuzumab(Pola, anti-CD79b)-containing regimen and were excluded from regimen-based comparisons because of the small sample. Although adding MTX yielded a numerically higher complete response (CR) rate than R-CHOP alone (93.3% vs 68.2%), 3-year progression-free survival (PFS; 54.5% vs 50.3%) and overall survival (OS; 68.5% vs 67.2%) were similar. By contrast, adding a BTKi was associated with significantly higher 3-year PFS (76.7% vs 50.3%; P=0.011) and OS (93.8% vs 67.2%; P=0.004) than R-CHOP alone. Compared with R-CHOP plus MTX, the BTKi-containing regimen was also associated with higher 3-year OS (93.8% vs 68.5%; P=0.043), while 3-year PFS was numerically but not significantly higher (76.7% vs 54.5%; P=0.099). Adding MTX to BTKi-containing therapy provided no additional PFS or OS benefit (P=0.099 and P=0.751), including in patients with CNS involvement (P=0.572 and P=1.000).
Six patients underwent auto-HSCT, including three as frontline consolidation and three after salvage therapy for relapsed disease; all were alive at last follow-up. All frontline recipients had stage IVB disease with bone marrow and lung involvement and IPI scores of 3, 4, and 4; two had CNS involvement and two had concomitant HLH. Their frontline regimens were R-CHOP plus MTX, R-Pola-CHP plus MTX, and BTKi-containing therapy, followed by auto-HSCT. All achieved CR and remained free from progression and death for 105.1, 27.8, and 7.1 months. In an exploratory unadjusted analysis of high-risk patients with bone marrow involvement, IPI ≥3, and multisite involvement, the 2-year PFS and OS rates were both 100% with frontline auto-HSCT (n=3), versus 56.0% and 62.7% without auto-HSCT (n=60); neither difference was statistically significant (PFS, P=0.182; OS, P=0.257). The salvage regimens for the three relapsed patients were ZR-DHAP, Pola-MTX, and R-GDP, followed by auto-HSCT; their post-relapse follow-up durations were 43.9, 10.7, and 12.7 months, with all three remaining alive. In an exploratory post-relapse analysis, 16 of 33 patients who did not undergo auto-HSCT died, and their median post-relapse OS was 15.0 months; the between-group difference was not statistically significant (P=0.140).
Conclusion: IVLBCL is clinically heterogeneous and predominantly presents with advanced-stage, high-risk, multisite disease. Adding a BTKi to R-CHOP was associated with better response and survival outcomes and may represent an effective treatment option. Auto-HSCT may provide durable disease control in selected patients with high-risk or relapsed IVLBCL and warrants further investigation.
DISCLOSURES
Yiao Di: No relevant conflicts of interest to declare.